Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination.

Area of Science:

• Neuroscience
• Pharmacology
• Medical Imaging

Background:

• Modafinil, a wake-promoting drug, is a first-line narcolepsy treatment.
• Its mechanism involves astroglial connexin-based gap junction communication.
• Flecainide, an inhibitor, enhances modafinil's effects on wakefulness and cognition.

Purpose of the Study:

• To investigate the effects of a combined modafinil and low-dose flecainide treatment (THN102) on cerebral glucose metabolism.
• To explore the neurobiological underpinnings of THN102's wake-promoting action.

Main Methods:

• Utilized 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) imaging in Sprague-Dawley rats.
• Administered vehicle, flecainide, modafinil, or THN102 to different animal groups.
• Analyzed regional brain glucose metabolism using voxel-to-voxel comparison via SPM8 software.

Main Results:

• THN102 significantly increased glucose metabolism in the cortex, striatum, and amygdala compared to controls or monotherapy.
• These activated regions are crucial for regulating sleep-wake cycles, emotions, and cognitive functions.
• Demonstrated quantitative modulation of these brain areas by THN102.

Conclusions:

• THN102 induces regional brain activation, evidenced by increased glucose metabolism.
• This study provides the first evidence of THN102's impact on brain metabolism.
• Findings support ongoing clinical trials of THN102 for narcolepsy treatment.